相关实验视频

Updated: Jun 3, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

奥西默提尼布作为第二线和第三线治疗,用于患有获得T790M突变的EGFR突变NSCLC患者的晚期和复发性EGFR突变NSCLC患者

Mu-Han Peng¹, Yen-Hsiang Huang^1,2,3, Kuo-Hsuan Hsu^1,2

¹Department of Chest Medicine, Taichung Veterans General Hospital, No. 1650, Sect. 4, Taiwan Boulevard, Taichung 407, Taiwan.

|January 8, 2025

概括

奥西默提尼布在患有T790M突变的EGFR突变非小细胞肺癌 (NSCLC) 患者中表现出有效性,无论它是否是EGFR突变.

科学领域:

在瘤学瘤学.
医学研究医学研究
药理学药理学是指药理学的学科.

背景情况:

奥西默提尼布是一种标准的序列疗法,用于T790M突变的先进和复发的表皮生长因子受体 (EGFR) 突变非小细胞肺癌 (NSCLC) 患者.
患者通常在接受第一代或第二代EGFR氨酸激酶抑制剂 (TKI) 治疗后接受奥西默蒂尼布.
对初始TKI疗法的耐药性需要对随后的治疗线进行评估.

研究的目的:

为了比较使用 osimertinib 作为二线治疗与第三线或后期治疗时的临床结果.
评估奥西默蒂尼布在不同治疗线的T790M突变的晚期和复发EGFR突变NSCLC中的疗效.

主要方法:

对158名先进和复发的EGFR T790M阳性NSCLC患者的回顾性分析,这些患者顺序接受奥西默提尼布.
这些患者之前曾经接受过一线治疗,包括gefitinib,erlotinib或afatinib.
患者接受奥西默提尼布二线治疗与第三线或后期治疗之间的结果进行了比较.

主要成果:

99名患者 (62.7%) 接受了奥西默提尼布作为二线治疗,59名患者 (37.3%) 接受了三线治疗或后期治疗.
无进展生存 (PFS) 的中位数为第二线的10.7个月,而≥3线的8.9个月.
从一线开始的中位数整体存活期 (OS) 为二线的73.2个月,而≥3线的57.5个月;没有发现统计学上显著的差异.

结论:

奥西默提尼布在EGFR突变性NSCLC和T790M突变中显示出有效性和临床益处,作为第二线和第三线或后期治疗.
这项研究支持在较早的EGFR-TKI治疗中对EGFR-TKI治疗产生耐药性的患者的后续治疗中继续使用 osimertinib.
奥西默提尼布为在顺序TKI治疗中进展的晚期和复发性NSCLC患者提供了有价值的治疗选择.

关键词:

在T790MM中.皮肤上生长因子受体.其他非小细胞肺癌.奥西米尔丁尼布 (osimertinib) 是一种氨酸激酶抑制剂氨酸激酶抑制剂

更多相关视频

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...